Investors might want to bet on Lexicon Pharmaceuticals (LXRX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year EndedDecember 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-04 ...

Exhibit 10.1 PREFERRED STOCK PURCHASE AGREEMENT dated as of March 11, 2024 by and among LEXICON PHARMACEUTICALS, INC. and THE PURCHASERS PARTY HERETO TABLE OF CONTENTS Page ARTICLE I PURCHASE; CLOSING 1 Section 1.1 Purchase and Sale 1 Section 1.2 Closing 1 Section 1.3 Closing Conditions 2 Section 1.4 Deliveries 3 ARTICLE II REPRESENTATIONS AND WARRANTIES 4 Section 2.1 Representations and Warranties of the Company 4 Section 2.2 Representations and Warranties of the Purchasers 14 ARTICLE III COVENANTS 16 Sect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Dela ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Carrie Siragusa - VP of Marketing Lonnel Coats - CEO Tom Garner - Chief Commercial Officer Craig Granowitz - Chief Medical Officer Jeffrey Wade - President and CFO Conference Call Participants Andrew Tsai - Jefferies Joseph Stringer - Needham & Company Operator Good day and welcome to the Lexicon Pharmaceuticals' Third Quarter 2023 Financial Results Conference Call. Today all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Inc. Andrew Tsai - Jefferies Group LLC Operator Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Results Conference Call May 2, 2023 5:00 PM ET Company Participants Carrie Siragusa - Executive Director, Corporate Strategy and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Dr. Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yigal Nochomovitz - Citigroup Joseph Stringer - Needham and Company Operator Good day everyone, and ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Carly Kenselaar – Citi Joseph Stringer – Needham & Company Operator Good afternoon, and welcom ...